1. Home
  2. CCS vs HRMY Comparison

CCS vs HRMY Comparison

Compare CCS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCS
  • HRMY
  • Stock Information
  • Founded
  • CCS 2000
  • HRMY 2017
  • Country
  • CCS United States
  • HRMY United States
  • Employees
  • CCS N/A
  • HRMY N/A
  • Industry
  • CCS Homebuilding
  • HRMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCS Consumer Discretionary
  • HRMY Health Care
  • Exchange
  • CCS Nasdaq
  • HRMY Nasdaq
  • Market Cap
  • CCS 1.7B
  • HRMY 1.8B
  • IPO Year
  • CCS 2014
  • HRMY 2020
  • Fundamental
  • Price
  • CCS $61.89
  • HRMY $34.00
  • Analyst Decision
  • CCS Buy
  • HRMY Strong Buy
  • Analyst Count
  • CCS 5
  • HRMY 9
  • Target Price
  • CCS $80.75
  • HRMY $54.44
  • AVG Volume (30 Days)
  • CCS 415.1K
  • HRMY 642.5K
  • Earning Date
  • CCS 07-23-2025
  • HRMY 08-05-2025
  • Dividend Yield
  • CCS 1.87%
  • HRMY N/A
  • EPS Growth
  • CCS 7.67
  • HRMY 13.13
  • EPS
  • CCS 9.70
  • HRMY 2.62
  • Revenue
  • CCS $4,352,977,000.00
  • HRMY $744,852,000.00
  • Revenue This Year
  • CCS N/A
  • HRMY $20.10
  • Revenue Next Year
  • CCS $4.98
  • HRMY $18.01
  • P/E Ratio
  • CCS $6.39
  • HRMY $13.10
  • Revenue Growth
  • CCS 11.97
  • HRMY 20.62
  • 52 Week Low
  • CCS $50.42
  • HRMY $26.47
  • 52 Week High
  • CCS $108.42
  • HRMY $41.61
  • Technical
  • Relative Strength Index (RSI)
  • CCS 65.62
  • HRMY 58.91
  • Support Level
  • CCS $57.50
  • HRMY $31.70
  • Resistance Level
  • CCS $63.74
  • HRMY $35.08
  • Average True Range (ATR)
  • CCS 2.29
  • HRMY 0.95
  • MACD
  • CCS 0.67
  • HRMY 0.27
  • Stochastic Oscillator
  • CCS 84.90
  • HRMY 71.80

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: